⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 3, 2025JAMA Psychiatry

Muscarinic Receptor Activators—What Is Their Place in Clinical Care?

Mikkel Højlund

View at Publisher

Ask AI

Bookmark

Share

Key Points

Muscarinic receptor activators may hold therapeutic potential for treating schizophrenia.
The viewpoint emphasizes their role in the management of this mental health condition.
Exploration of their clinical application is necessary to optimize treatment outcomes.
Understanding the implications of these activators can yield insights into new care strategies.

Implication

This viewpoint discusses muscarinic receptor activators for schizophrenia, suggesting a potential role in clinical care.

Abstract

This Viewpoint discusses the role of muscarinic receptor activators in the treatment of schizophrenia.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mikkel Højlund (2025) studied this question.

synapsesocial.com/papers/69337d09b3f947a0a125aaf9 https://doi.org/10.1001/jamapsychiatry.2025.3636

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Muscarinic Acetylcholine Receptor Activators as Transformative Therapeutics for Schizophrenia2025
2Targeting muscarinic receptors for treating schizophreniaEarly-Phase Clinical Trial · 2026 · 3 citations
3591. MUSCARINIC RECEPTORS AND THE MOLECULAR PATHOLOGY OF SCHIZOPHRENIA2025
4Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasmReview · 2026
5Exploring cholinergic dysfunctions in schizophrenia as targets for a new generation of antipsychotics- The current level of evidence2025

More related papers

“Increasing dopamine synthesis capacity in the dorsal striatum and tonic acetylcholine: implications for the new muscarinic agents in the treatment of schizophrenia”2026
Efficacy and safety of cholinergic modulators in patients with schizophrenia: meta-analysis of randomised controlled trials2025
Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M1 and M4 receptors2025

More from JAMA Psychiatry

Multimodal Machine Learning–Based Prediction of Relapse in Major Depressive DisorderWed,
Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson DiseaseWed,